Multidrug-resistant and extensively drug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 3, 2009, Pages 304-311

  Chiang, Chen Yuan ^a,c   Yew, W W ^b  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b GRANTHAM HOSPITAL   (Hong Kong)

^c NONE   (Taiwan)

Author keywords

Extensively drug resistant; Multidrug resistant; Tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; PLACEBO; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GAMMA INTERFERON; RIFAMPICIN; STREPTOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIUM ISOLATE; CLINICAL TRIAL; DRUG MEGADOSE; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MULTIDRUG RESISTANCE; PEER REVIEW; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

AFRICA; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; IMMUNOASSAY; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 62349133683     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. World Health Organization. The WH(MUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Report no. 4. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO. 2008. http://whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008.394_eng.pdf Accessed December 2008.
2. Javaid A, Hasan R, Zafar A, et al. Prevalence of primary multi-drug resistance to anti-tuberculosis drugs in Pakistan. Int J Tuberc Lung Dis 2008; 12: 326-331.
3. Mokaddas E, Ahmad S, Samir I. Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996-2005. Int J Tuberc Lung Dis 2008; 12: 319-325.
4. Jugheli L, Rigouts L, Shamputa I C, Bram de Rijk W, Portaels F. High levels of resistance to second-line anti-tuberculosis drugs among prisoners with pulmonary tuberculosis in Georgia. Int J Tuberc Lung Dis 2008; 12: 561-566.
5. Karagoz T, Pazarli P, Mocin O Y, et al. Evaluation of drug resistance in pulmonary tuberculosis patients at Sureyyapasa Chest Diseases Hospital, Istanbul, Turkey. Int J Tuberc Lung Dis 2008; 12: 631-635.
6. Lai C C, Tan C K, Huang Y T, et al. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan. Clin Infect Dis 2008; 47: e57-63.
7. Khue P M, Phuc T Q, Hung N V, Jarlier V, Robert J. Drug resistance and HIV co-infection among pulmonary tuberculosis patients in Haiphong City, Vietnam. Int J Tuberc Lung Dis 2008; 12: 763-768.
8. Dubrovina I, Miskinis K, Lyepshina S, et al. Drug-resistant tuberculosis and HIV in Ukraine: a threatening convergence of two epidemics? Int J Tuberc Lung Dis 2008; 12: 756-762.
9. Law W S, Yew W W, Chiu Leung C, et al. Risk factors for multidrug-resistant tuberculosis in Hong Kong. Int J Tuberc Lung Dis 2008; 12: 1065-1070.
10. Schmid D, Fretz R, Kuo H W, et al. An outbreak of multidrug-resistant tuberculosis among refugees in Austria, 2005-2006. Int J Tuberc Lung Dis 2008; 12: 1190-1195.
11. van Ingen J, Boeree M J, Wright A, van der Laan T, Dekhuijzen PN, van Soolingen D. Second-line drug resistance in multidrug-resistant tuberculosis cases of various origins in the Netherlands. Int J Tuberc Lung Dis 2008; 12: 1295-1299.
12. World Health Organization. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. WHO/TB/97.229. Geneva, Switzerland: WHO, 1997.
13. World Health Organization. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Report no. 2. Prevalence and trends. WHO/CDC/TB/2000.278. Geneva, Switzerland: WHO, 2000.
14. World Health Organization. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Report no. 3. WHO/ CDS/TB/2004.343. Geneva, Switzerland: WHO, 2004.
15. Cohen T, Coljin C, Wright A, Zignol M, Pym A, Murray M. Challenges in estimating the total burden of drug-resistant tuberculosis. Am J Respir Crit Care Med 2008; 177: 1302-1306.
16. Cohen T, Colijn C, Finklea B, et al. Are survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation study. PLoS ONE. 2008 Jun 4; 3(6): e2363.
17. Ben Amor Y, Nemser B, Singh A, Sankin A, Schluger N. Under-reported threat of multidrug-resistant tuberculosis in Africa. Emerg Infect Dis 2008; 14: 1345-1352.
18. Mphahlele M, Syre H, Valvatne H, et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol 2008; 46: 3459-3464.
19. Umubyeyi A, Rigouts L, Shamputa I C, Dediste A, Struelens M, Portaels F. Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda. Int J Infect Dis 2008; 12: 152-156.
20. Huang T S, Liu Y C, Sy C L, Chen Y S, Tu H Z, Chen B C. In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob Agents Chemother 2008; 52: 2226-2227.
21. Oeltmann J E, Varma J K, Ortega L, et al. Multidrug-resistant tuberculosis outbreak among US-bound Hmong refugees, Thailand, 2005. Emerg Infect Dis 2008; 14: 1715-1721.
22. Satti H, Seung K, Keshavjee S, Furin J. Extensively drug-resistant tuberculosis, Lesotho. Emerg Infect Dis 2008; 14: 992-993.
23. Mlambo C K, Warren R M, Poswa X, Victor T C, Duse A G, Marais E. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis 2008; 12: 99-104.
24. Andrews J R, Gandhi N R, Moodley P, et al. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis 2008; 198: 1582-1589.
25. Cox H S, Sibilia K, Feuerriegel S, et al. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N Engl J Med 2008; 359: 2398-2400.
26. Marttila H J, Mäkinen J, Marjamäki M, Ruutu P, Somi H. Molecular genetics of drug-resistant Mycobacterium tuberculosis isolates in Finland, 1995-2004. Int J Tuberc Lung Dis 2008; 12: 338-343.
27. Ano H, Matsumoto T, Suetake T, et al. Relationship between the isoniazid-resistant mutation katGS315T and the prevalence of MDR-/XDR-TB in Osaka, Japan. Int J Tuberc Lung Dis 2008; 12: 1300-1305.
28. Takahashi K, Hasegawa Y, Abe T, et al. SLC11A1 (formerly (NRAMP1) polymorphisms associated with multidrug-resistant tuberculosis. Tuberculosis 2008; 88: 52-57.
29. Iwamoto T, Yoshida S, Suzuki K, Wada T. Population structure analysis of the Mycobacterium tuberculosis Beijing family indicates an association between certain sublineages and multidrug resistance. Antimicrob Agents Chemother 2008; 52: 3805-3809.
30. Ang C F, Ong C S, Rukmana A, et al. An overview of the phenotypic and genotypic characteristics of multidrug-resistant Mycobacterium tuberculosis isolates from four Asian countries. J Med Microbiol 2008; 57: 1039-1040.
31. Prammananan T, Cheunoy W, Taechamahapun D, et al. Distribution of rpoB mutations among multidrug-resistant Mycobacterium tuberculosis (MDRTB) strains from Thailand and development of a rapid method for mutation detection. Clin Microbiol Infect 2008; 14: 446-453.
32. Kim H J, Chung D H, Kim M J, et al. Decreased phosphorylation of STAT-1, STAT-4 and cytokine release in MDR-TB patients with primary resistance. Int J Tuberc Lung Dis 2008; 12: 1071-1076.
33. Grandjean L, Martin L, Gilman R H, et al. Tuberculosis diagnosis and multidrug resistance testing by direct sputum culture in selective broth without decontamination or centrifugation. J Clin Microbiol 2008; 46: 2339-2344.
34. Ejigu G S, Woldeamanuel Y, Shah N S, Gebyehu M, Selassie A, Lemma E. Microscopic-observation drug susceptibility assay provides rapid and reliable identification of MDR-TB. Int J Tuberc Lung Dis 2008; 12: 332-337.
35. Nie Fhogartaigh C J, Vargas-Prada S, Huancaré V, Lopez S, Rodríguez J, Moore D A J. Physician-initiated courtesy MODS testing for TB and MDR-TB diagnosis and patient management. Int J Tuberc Lung Dis 2008; 12: 555-560.
36. Ingham C J, Ayad A B, Nolsen K, Mulder B. Rapid drug susceptibility testing of mycobacteria by culture on a highly porous ceramic support. Int J Tuberc Lung Dis 2008; 12: 645-650.
37. van Doom H R, An D D, de Jong M D, et al. Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR. Int J Tuberc Lung Dis 2008; 12: 736-742.
38. Asencios L, Yale G, Yagui M, et al. Programmatic implementation of rapid DST for Mycobacterium tuberculosis in Peru, Int J Tuberc Lung Dis 2008; 12: 743-749.
39. Tho D Q, Ha D T, Duy P M, et al. Comparison of MAS-PCR and GenoType MTBDR assay for the detection of rifampicinresistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008; 12: 1306-1312.
40. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 system. Int J Tuberc Lung Dis 2008; 12: 1449-1455.
41. Causse M, Ruiz P, Gutierrez J B, Zerolo J, Casai M. Evaluation of new GenoType® R MTBDRplus for detection of resistance in cultures and direct specimens for Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008; 12: 1456-1460.
42. Robledo J, Mejia GI, Paniagua L, Martin A, Guzman A. Rapid detection of rifampicin and isoniazid resistance in Mycobactenum tuberculosis by the direct thin-layer agar method. Int J Tuberc Lung Dis 2008; 12: 1482-1484.
43. Farnia P, Masjedi M R, Mohammadi F, et al. Colorimetric detection of multidrug-resistant or extensively drug-resistant tuberculosis by use of malachite green indicator dye. J Clin Microbiol 2008; 46: 796-799.
44. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman M E. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Grit Care Med 2008; 177: 787-792.
45. Ling D I, Zwerling A A, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-reistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32: 1165-1174.
46. Ling D I, Zwerling A A, Pai M. Rapid diagnosis of drug-resistant TB using line probe assays: from evidence to policy. Expert Rev Resp Med 2008; 2: 583-588.
47. Gegia M, Mdivani N, Mendes R E, et al. Prevalence of and molecular basis for tuberculosis drug resistance in the Republic of Georgia: validation of a QIAplex system for detection of drug resistance-related mutations. Antimicrob Agents Chemother 2008; 52: 725-729.
48. Affolabi D, Odoun M, Sanoussi N, et al. Rapid and inexpensive detection of multidrug-resistant Mycobacterium tuberculosis with the nitrate reductase assay using liquid medium and direct application to sputum samples. J Clin Microbiol 2008; 46: 3243-3245.
49. Affolabi D, Sanoussi N 'D, Odoun M, et al. Rapid detection of multidrug-resistant Mycobacterium tuberculosis in Cotonou (Benin) using two low-cost colorimetric methods: resazurm and nitrate reductase assays. J Med Microbiol 2008; 57: 1024-1027.
50. Martin A, Panaiotov S, Portaels F, Hoffner S, Palomino J C, Angeby K. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2008; 62: 56-64.
51. Springer B, Calligaris-Maibach R C, Ritter C, Bottger E C. Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping. J Clin Microbiol 2008; 46: 4064-4067.
52. Acuna-Villaorduna C, Vassall A, Henostroza G, et al. Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis 2008; 47: 487-495.
53. Palomino J C, Martin A, Von Groll A, Portaels F. Rapid culture-based methods for drug-resistance detection in Mycobacterium tuberculosis. J Microbiol Methods 2008; 75: 161-166.
54. Shin S S, Yagui M, Ascencios L, et al. Scale-up of multidrug-resistant tuberculosis laboratory services, Peru. Emerg Infect Dis 2008; 14: 701-708.
55. Mak A, Thomas A, Del Granado M, Zaleskis R, Mouzafarova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008; 178: 306-312.
56. Katiyar S K, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008; 12: 129-145.
57. Moulding T. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. (Correspondence] Int J Tuberc Lung Dis 2008; 12: 1102.
58. Petty T L, Mitchell R S. Successful treatment of advanced isoniazid and streptomycin-resistant pulmonary tuberculosis with ethionamide, pyrazinamide, and isoniazid. Am Rev Respir Dis 1962; 86: 503-512.
59. Grahmann P R, Braun R K. A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study. Int J Tuberc Lung Dis 2008; 12: 636-644.
60. Masjedi M R, Tabarsi P, Chitsaz E, et al. Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002-2006. Int J Tuberc Lung Dis 2008; 12: 750-755.
61. Shean K P, Willcox P A, Siwendu S N, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis 2008; 12: 1182-1189.
62. Franke M F, Appleton S C, Bayona J, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis 2008; 46: 1844-1851.
63. von Gottberg A, Klugman K P, Cohen C, et al. Emergence of levofloxacin-non-susceptible Streptococcus pneumonias and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 2008; 371: 1108-1113.
64. Caminero J A. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Programme implementation. Im J Tuberc Lung Dis 2008; 12: 869-877.
65. Padayatchi N, Friedland G. Decentralised managment of drug-resistant tuberculosis (MDR- and XDR-TB) in South Africa: an alternative model of care. Int J Tuberc Lung Dis 2008; 12: 978-980.
66. Scano F, Vitoria M, Burman W, Harries A D, Gilks C F, Havlir D. Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings. Int J Tuberc Lung Dis 2008; 12: 1370-1375.
67. Mitnick C D, Shin S S, Seung K J, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-574.
68. Kwon Y S, Kim Y H, Suh G Y, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008; 47: 496-502.
69. Park S K, Kim J H, Kang H, Cho J S, Smego RA Jr. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int J Infect Dis 2008 Sep 1 [Epub ahead of print].
70. Jeon C Y, Hwang S H, Min J H, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis 2008; 46: 42-49.
71. Shah N S, Pratt R, Armstrong L, Robison V, Castro K G, Cegielski J P. Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA 2008; 300: 2153-2160.
72. Keshavjee S, Gelmanova I Y, Farmer P E, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372: 1403-1409.
73. Chan E D, Strand M J, Iseman M D. Treatment outcomes in extensively drug resistant tuberculosis. [Correspondence] N Engl J Med 2008; 359: 657-659.
74. Kim H R, Hwang S S, Kim H J, Lee S M, Yoo C G, Kim Y W, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45: 1290-1295.
75. Migliori G B, Lange C, Girardi E, et al. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results. Clin Infect Dis 2008; 46: 958-959.
76. Migliori G B, Lange C, Girardi E, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? [Correspondence] Eur Respir J 2008; 31: 904-905.
77. Migliori G B, Lange C, Centi R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008; 31: 1155-1159.
78. Eker B, Ortmann J, Migliori G B, et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14: 1700-1706.
79. Feja K, McNelley E, Tran C S, Burzynski J, Saiman L: Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003. Pediatr Infect Dis J 2008; 27: 907-912.
80. Jones KDJ, Hesketh T, Yudkin J. Extensively drug-resistant tuberculosis in sub-Saharan Africa: an emerging public-health concern. Trans R Soc Trop Med Hyg 2008; 102: 219-224.
81. Yew W W, Leung C C. Management of multidrug-resistant tuberculosis: update 2007. Respirology 2008; 13: 21-46.
82. Chan E D, Iseman M D. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis 2008; 21: 587-595.
83. Mitnick C D, Appleton S C, Shin S S. Epidemiology and treatment of multidrug resistant tuberculosis. Semin Respir Crit Care Med 2008; 29: 499-524.
84. Chiang C-Y, Enarson D A, Fujiwara P I, Van Deun A, Lee J J. Strategies of extensively drug-resistant TB risk management for health workers and other care givers. Expert Rev Resp Med 2008; 2: 47-54.
85. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
86. Selgelid MJ, Kelly P M, Sleigh A. Ethical challenges in TB control in the era of XDR-TB. Im J Tuberc Lung Dis 2008; 12: 231-235.
87. Cobelens F G J, Heldal E, Kimerling M E, et al. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PloS Med 2008; 5(7): e150.
88. Fauci A S, NIAID Tuberculosis Working Group. Multidrug resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research. J Infect Dis 2008; 197: 1493-1498.